Drug Type Autologous CAR-T |
Synonyms 合成性T细胞受体抗原受体, YTS 104, YTS104 |
Target |
Mechanism LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization BriSTAR Immunotech LimitedStartup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 1 | CN | BriSTAR Immunotech LimitedStartup | 15 Jun 2023 |
Refractory acute myeloid leukemia | Phase 1 | - | 30 Nov 2022 | |
Acute Myeloid Leukemia | Phase 1 | CN | BriSTAR Immunotech LimitedStartup | - |
Chronic Myelomonocytic Leukemia | IND Application | CN | BriSTAR Immunotech LimitedStartup | 03 Nov 2023 |
Relapsing acute myeloid leukemia | IND Application | CN | BriSTAR Immunotech LimitedStartup | 03 Nov 2023 |